High telomerase RNA expression level is an adverse prognostic factor for favorable-histology Wilms' tumor

Journal of Clinical Oncology

Volumn 23, Issue 36, 2005, Pages 9138-9145

  Dome, Jeffrey S ^a   Bockhold, Carol A ^a   Li, Sierra M ^a   Baker, Scott D ^a   Green, Daniel M ^a   Perlman, Elizabeth J ^a   Hill, D Ashley ^a   Breslow, Norman E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; TELOMERASE; DNA BINDING PROTEIN; RNA; TERT PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFANT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEPHROBLASTOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA DEGRADATION; RNA SPLICING; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; UNIVARIATE ANALYSIS; BIOSYNTHESIS; CASE CONTROL STUDY; GENETICS; KIDNEY TUMOR; NEWBORN; POLYMERASE CHAIN REACTION; RISK FACTOR;

CASE-CONTROL STUDIES; CHILD, PRESCHOOL; COHORT STUDIES; DNA-BINDING PROTEINS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; KIDNEY NEOPLASMS; MALE; MULTIVARIATE ANALYSIS; POLYMERASE CHAIN REACTION; PROGNOSIS; RISK FACTORS; RNA; TELOMERASE; TUMOR MARKERS, BIOLOGICAL; WILMS TUMOR;

EID: 33644825242     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.00.562     Document Type: Article

References (56)

1. Jemal A, Tiwari RC, Murray T, et al: Cancer statistics, 2004. CA Cancer J Clin 54:8-29, 2004
2. Kalapurakal JA, Dome JS, Perlman EJ, et al: Management of Wilms' tumour: Current practice and future goals. Lancet Oncol 5:37-46, 2004
3. Nakamura TM, Morin GB, Chapman KB, et al: Telomerase catalytic subunit homologs from fission yeast and human. Science 277:955-959, 1997
4. Feng J, Funk WD, Wang SS, et al: The RNA component of human telomerase. Science 269:1236-1241, 1995
5. Counter CM, Meyerson M, Eaton EN, et al: Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene 16:1217-1222, 1998
6. Kim NW, Piatyszek MA, Prowse KR, et al: Specific association of human telomerase activity with immortal cells and cancer. Science 266:2011-2015, 1994
7. Shay JW, Bacchetti S: A survey of telomerase activity in human cancer. Eur J Cancer 33:787-791, 1997
8. Hiyama E, Hiyama K: Clinical utility of telomerase in cancer. Oncogene 21:643-649, 2002
9. Dome JS, Chung S, Bergemann T, et al: High telomerase reverse transcriptase (hTERT) messenger RNA level correlates with tumor recurrence in patients with favorable histology Wilms' tumor. Cancer Res 59:4301-4307, 1999
10. Grundy PE, Green DM, Coppes MJ, et al: Renal tumors, in Pizzo PA, Poplack DG (eds): Principles and Practice of Pediatric Oncology (ed 4). Philadelphia, PA, Lippincott Williams & Wilkins, 2002, pp 865-893
11. Prentice RL: A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika 73:1-11, 1986
12. Kim NW, Wu F: Advances in quantification and characterization of telomerase activity by the telomeric repeat amplification protocol (TRAP). Nucleic Acids Res 25:2595-2597, 1997
13. Piatyszek MA, Kim NW, Weinrich SL, et al: Detection of telomerase activity in human cells and tumors by a telomeric repeat amplification protocol (TRAP). Methods Cell Sci 17:1-15, 1995
14. Heid CA, Stevens J, Livak KJ, et al: Real time quantitative PCR. Genome Res 6:986-994, 1996
15. Gibson UEM, Heid CA, Williams PM: A novel method for real time quantitative RT-PCR. Genome Res 6:995-1001, 1996
16. Bieche I, Nogues C, Paradis V, et al: Quantitation of hTERT gene expression in sporadic breast tumors with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res 6:452-459, 2000
17. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
18. Lin DY, Ying Z: Cox regression with incomplete covariate measurements. J Am Stat Assoc 88:1341-1349, 1993
19. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
20. Meyerson M, Counter CM, Eaton EN, et al: HEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90:785-795, 1997
21. Kilian A, Bowtell DDL, Abud H, et al: Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types. Hum Mol Genet 6:2011-2019, 1997
22. Ulaner GA, Hu JF, Vu TH, et al: Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts. Cancer Res 58:4168-4172, 1998
23. Wick M, Zubov D, Hagen G: Genomic organization and promoter characterization of the gene encoding the human telomerase reverse transcriptase (hTERT). Gene 232:97-106, 1999
24. Hisatomi H, Ohyashiki K, Ohyashiki JH, et al: Expression profile of a gamma-deletion variant of the human telomerase reverse transcriptase gene. Neoplasia 5:193-197, 2003
25. Hiyama E, Hiyama K, Yokoyama T, et al: Correlating telomerase activity levels with human neuroblastoma outcomes. Nat Med 1:249-255, 1995
26. Poremba C, Scheel C, Hero B, et al: Telomerase activity and telomerase subunits gene expression patterns in neuroblastoma: A molecular and immunohistochemical study establishing prognostic tools for fresh-frozen and paraffin-embedded tissues. J Clin Oncol 18:2582-2592, 2000
27. Choi LM, Kim NW, Zuo JJ, et al: Telomerase activity by TRAP assay and telomerase RNA (hTR) expression are predictive of outcome in neuroblastoma. Med Pediatr Oncol 35:647-650, 2000
28. Krams M, Hero B, Berthold F, et al: Full-length telomerase reverse transcriptase messenger RNA is an independent prognostic factor in neuroblastoma. Am J Pathol 162:1019-1026, 2003
29. Hiyama E, Yamaoka H, Matsunaga T, et al: High expression of telomerase is an independent prognostic indicator of poor outcome in hepatoblastoma. Br J Cancer 91:972-979, 2004
30. Sanders RP, Drissi R, Billups CA, et al: Telomerase expression predicts unfavorable outcome in osteosarcoma. J Clin Oncol 22:3790-3797, 2004
31. Verstovsek S, Manshouri T, Smith FO, et al: Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia. Cancer 97:2212-2217, 2003
32. Hamad NM, Banik SS, Counter CM: Mutational analysis defines a minimum level of telomerase activity required for tumourigenic growth of human cells. Oncogene 21:7121-7125, 2002
33. Wang H, Blackburn EH: De novo telomere addition by Tetrahymena telomerase in vitro. EMBO J 16:866-879, 1997
34. Bednenko J, Melek M, Greene EC, et al: Developmental regulated initiation of DNA synthesis by telomerase: Evidence for factor-assisted de novo telomere formation. EMBO J 16:2507-2518, 1997
35. Kramer KM, Haber JE: New telomeres in yeast are initiated with a highly selected subset of TG1-3 repeats. Genes Dev 7:2345-2356, 1993
36. Kondo Y, Kondo S, Tanaka Y, et al: Inhibition of telomerase increases the susceptibility of human malignant glioblastoma cells to cisplatin-induced apoptosis. Oncogene 16:2243-2248, 1998
37. Ludwig A, Saretzki G, Holm PS, et al: Ribozyme cleavage of telomerase mRNA sensitizes breast epithelial cells to inhibitors of topoisomerase. Cancer Res 61:3053-3061, 2001
38. Yuan Z, Mei HD: Inhibition of telomerase activity with hTERT antisense increases the effect of CDDP-induced apoptosis in myeloid leukemia. Hematol J 3:201-205, 2002
39. Misawa M, Tauchi T, Sashida G, et al: Inhibition of human telomerase enhances the effect of chemotherapeutic agents in lung cancer cells. Int J Oncol 21:1087-1092, 2002
40. Stewart SA, Hahn WC, O'Connor BF, et al: Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci U S A 99:12606-12611, 2002
41. Chang S, Khoo CM, Naylor ML, et al: Telomere-based crisis: Functional differences between telomerase activation and ALT in tumor progression. Genes Dev 17:88-100, 2003
42. Hiyama E, Yokoyama T, Tatsumoto N, et al: Telomerase activity in gastric cancer. Cancer Res 55:3258-3262, 1995
43. Langford LA, Piatyszek MA, Xu R, et al: Telomerase activity in ordinary meningiomas predicts poor outcome. Hum Pathol 28:416-420, 1997
44. Marchetti A, Bertacca G, Buttitta F, et al: Telomerase activity as a prognostic indicator in stage 1 non-small cell lung cancer. Clin Cancer Res 5:2077-2081, 1999
45. Wang L, Soria JC, Kemp BL, et al: HTERT expression is a prognostic factor of survival in patients with stage I non-small cell lung cancer. Clin Cancer Res 8:2883-2889, 2002
46. Blasco MA, Rizen M, Greider CW, et al: Differential regulation of telomerase activity and telomerase RNA during multi-stage tumorigenesis. Nat Genet 12:200-204, 1996
47. Soder AI, Hoare SF, Muir S, et al: Amplification, increased dosage and in situ expression of the telomerase RNA gene in human cancer. Oncogene 14:1013-1021, 1997
48. Yi X, Tesmer VM, Savre-Train I, et al: Both transcriptional and posttranscriptional mechanisms regulate human telomerase template RNA levels. Mol Cell Biol 19:3989-3997, 1999
49. Yashima K, Maitra A, Timmons CF, et al: Expression of the RNA component of telomerase in Wilms tumor and nephrogenic rest recapitulates renal embryogenesis. Hum Pathol 29:536-542, 1998
50. Guilleret I, Yan P, Guillou L, et al: The human telomerase RNA gene (hTERC) is regulated during carcinogenesis but is not dependent on DNA methylation. Carcinogenesis 23:2025-2030, 2002
51. Maitra A, Yashima K, Rathi A, et al: The RNA component of telomerase as a marker of biologic potential and clinical outcome in childhood neuroblastic tumors. Cancer 85:741-749, 1999
52. Poremba C, Shroyer KR, Frost M, et al: Telomerase is a highly sensitive and specific molecular marker in fine-needle aspirates of breast lesions. J Clin Oncol 17:2020-2026, 1999
53. Poremba C, Heine B, Diallo R, et al: Telomerase as a prognostic marker in breast cancer: High-throughput tissue microarray analysis of hTERT and hTR. J Pathol 198:181-189, 2002
54. Vulliamy T, Marrone A, Goldman F, et al: The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature 413:432-435, 2001
55. Hathcock KS, Hemann MT, Opperman KK, et al: Haploinsufficiency of mTR results in defects in telomere elongation. Proc Natl Acad Sci U S A 99:3591-3596, 2002
56. Chiang YJ, Hemann MT, Hathcock KS, et al: Expression of telomerase RNA template, but not telomerase reverse transcriptase, is limiting for telomere length maintenance in vivo. Mol Cell Biol 24:7024-7031, 2004